150 related articles for article (PubMed ID: 38443329)
81. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
82. Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan-based regimen.
Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Kobayashi Y; Miura Y; Lefor AK; Yamamoto H
Kaohsiung J Med Sci; 2018 Aug; 34(8):456-460. PubMed ID: 30041763
[TBL] [Abstract][Full Text] [Related]
83. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.
Gisbert JP; Morena F
Aliment Pharmacol Ther; 2006 Jan; 23(1):35-44. PubMed ID: 16393278
[TBL] [Abstract][Full Text] [Related]
84. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication.
Kusunoki M; Yuki M; Ishitobi H; Kobayashi Y; Nagaoka M; Takahashi Y; Fukuba N; Komazawa Y; Shizuku T; Kinoshita Y
Intern Med; 2019 Jun; 58(11):1549-1555. PubMed ID: 30713328
[TBL] [Abstract][Full Text] [Related]
85. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
Okubo H; Akiyama J; Kobayakawa M; Kawazoe M; Mishima S; Takasaki Y; Nagata N; Shimada T; Yokoi C; Komori S; Kimura K; Hisada Y; Iwata E; Watanabe K; Yanagisawa N; Shiroma S; Shimomura A; Okahara K; Cho H; Uemura N
J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
[TBL] [Abstract][Full Text] [Related]
86. Vonoprazan is Not Inferior to Proton Pump Inhibitors in Bismuth-containing Quadruple Therapy for Helicobacter pylori Eradication: A Meta-analysis of 10 Studies From East Asia.
Cheng Y; Yang L; Xu S; Zhang C
J Clin Gastroenterol; 2024 Apr; ():. PubMed ID: 38607993
[TBL] [Abstract][Full Text] [Related]
87. Vonoprazan-amoxicillin dual therapy for
Zhou BG; Mei YZ; Jiang X; Zheng AJ; Ding YB
Saudi J Gastroenterol; 2023; 29(6):347-357. PubMed ID: 37602635
[TBL] [Abstract][Full Text] [Related]
88. Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: A large-scale prospective, single-center clinical trial in China.
Zhou JJ; Shi X; Zheng SP; Tang D; Cai T; Yao Y; Wang F
Helicobacter; 2020 Dec; 25(6):e12755. PubMed ID: 32914914
[TBL] [Abstract][Full Text] [Related]
89. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
Ang D; Koo SH; Chan YH; Tan TY; Soon GH; Tan CK; Lin KW; Krishnasamy-Balasubramanian JK; Wong YJ; Kumar R; R R; Tan Y; Ong PJ; Tan YJ; Li JW; Kwek AB; Ang TL
Aliment Pharmacol Ther; 2022 Aug; 56(3):436-449. PubMed ID: 35665947
[TBL] [Abstract][Full Text] [Related]
90. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
Hsu PI; Chen WC; Tsay FW; Shih CA; Kao SS; Wang HM; Yu HC; Lai KH; Tseng HH; Peng NJ; Chen A; Kuo CH; Wu DC;
Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865
[TBL] [Abstract][Full Text] [Related]
91. Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan.
Ratana-Amornpin S; Sanglutong L; Eiamsitrakoon T; Siramolpiwat S; Graham DY; Mahachai V
Helicobacter; 2023 Dec; 28(6):e13019. PubMed ID: 37723133
[TBL] [Abstract][Full Text] [Related]
92. Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori.
Chen XX; Chen YX; Bi HX; Zhao X; Zhang LF; Liu JY; Shi YQ
J Dig Dis; 2022 Oct; 23(10):568-576. PubMed ID: 36415112
[TBL] [Abstract][Full Text] [Related]
93. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
Kim SB; Lee SH; Kim KO; Jang BI; Kim TN
Korean J Gastroenterol; 2015 Nov; 66(5):261-7. PubMed ID: 26586348
[TBL] [Abstract][Full Text] [Related]
94. Antofloxacin-based bismuth quadruple therapy is safe and effective in Helicobacter pylori eradication: A prospective, open-label, randomized trial.
He XJ; Zeng XP; Jiang CS; Liu G; Li DZ; Wang W
Arab J Gastroenterol; 2021 Mar; 22(1):47-51. PubMed ID: 33551347
[TBL] [Abstract][Full Text] [Related]
95. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.
Gisbert JP; Calvet X
Aliment Pharmacol Ther; 2011 Sep; 34(6):604-17. PubMed ID: 21745241
[TBL] [Abstract][Full Text] [Related]
96. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Sue S; Shibata W; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
J Gastroenterol Hepatol; 2019 Apr; 34(4):686-692. PubMed ID: 30151994
[TBL] [Abstract][Full Text] [Related]
97. A randomized controlled comparison of three quadruple therapy regimens in a population with low Helicobacter pylori eradication rates.
Sotudehmanesh R; Malekzadeh R; Fazel A; Massarrat S; Ziad-Alizadeh B; Eshraghian MR
J Gastroenterol Hepatol; 2001 Mar; 16(3):264-8. PubMed ID: 11339416
[TBL] [Abstract][Full Text] [Related]
98. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection.
Lee ST; Lee DH; Lim JH; Kim N; Park YS; Shin CM; Jo HJ; Song IS
Gut Liver; 2015 Jul; 9(4):478-85. PubMed ID: 25071068
[TBL] [Abstract][Full Text] [Related]
99. Eradication Rate of
Liu RP; Romero R; Sarosiek J; Dodoo C; Dwivedi AK; Zuckerman MJ
South Med J; 2018 Jan; 111(1):51-55. PubMed ID: 29298370
[TBL] [Abstract][Full Text] [Related]
100. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
Maruyama M; Tanaka N; Kubota D; Miyajima M; Kimura T; Tokutake K; Imai R; Fujisawa T; Mori H; Matsuda Y; Wada S; Horiuchi A; Kiyosawa K
Can J Gastroenterol Hepatol; 2017; 2017():4385161. PubMed ID: 28349044
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
